

MAY. 18. 2005 1:02PM AVENTIS US PAT DEPT
TO: US USPTO GENERAL

RECEIVED
CENTRAL FAX CENTER

NO. 5345 P. 1

MAY 18 2005

PTO/SB/21 (08-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

17

Application Number

10/787,367

Filing Date

February 26, 2004

First Named Inventor

Michael GRAUPE et al.

Art Unit

1626

Examiner Name

Coppins, Janet


Attorney Docket Number

USA2001/0143 US CNT

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <div style="border: 1px solid black; padding: 5px; width: 150px; height: 40px; margin-top: 5px;">1. Form 1449 2. IDS Fee sheet</div>
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund	<input type="checkbox"/> Remarks
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Landscape Table on CD	
<input checked="" type="checkbox"/> Information Disclosure Statement		
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		


RECEIVED
MAY 19 2005
OPIE / JCWS

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Joseph ROSSI		
Date	May 18, 2005	Reg. No.	47038

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306 ; Total No. of Pages Transmitted: 17)

Signature			
Typed or printed name	Paul Irvine	Date	May 18, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CENTRAL FAX CENTER

In re Application of
GRAUPE, et al.

Examiner: Coppins, Janet **MAY 18 2005**

Application No.: **10/787,367**


Art Unit: **1626**

Filed: **February 26, 2004**

Title: **NOVEL COMPOUNDS AND
 COMPOSITIONS AS CATHEPSIN
 INHIBITORS**

Certificate of Mailing or Transmission
 I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.
 Date of Deposit **May 18, 2005**

Printed Name of Person Signing Certificate **Paul Irvine**

Signature 


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.


Please charge Deposit Account No. 18-1982 in the amount of \$180.00. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,


 Joseph D. Rossi, Reg. No. 47,038
 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
 Patent Department
 Route #202-206 / P.O. Box 6800
 Bridgewater, NJ 08807-0800
 Telephone (908) 231-3410
 Telefax (908) 231-2626

Aventis Docket No. USAV2001/0143 US CNT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
GRAUPE, et al.Application No.: **10/787,367**Filed: **February 26, 2004**Title: **NOVEL COMPOUNDS AND
COMPOSITIONS AS CATHEPSIN
INHIBITORS**Examiner: **Coppins, Janet**Art Unit: **1626****TELEFAX CERTIFICATE**I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, on**May 18, 2005**
Date of TransmissionSignature **INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(b), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

05/19/2005 JBALINAN 00000043 181982 10787367

01 FC:1806 180.00 DA

(b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

(1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;

(2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or

(3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:


The items listed on pages 1 –13 of the attached PTO-1449 have been previously submitted to the Patent Office or cited by the Examiners during the prosecution of the following patents or patent applications commonly owned by the assignees of record of the present case:

U.S. Patent Nos. 6,576,630, 6,506,733, 6,455,502 and 6,492,362; and

U.S. Patent Application Nos. 10/035,783, 10/478,632, 10/719,080, 10/418,183 and 10/294,526.

Therefore, a copy of the reference is not enclosed with this Information Disclosure Statement. However, the applicant will furnish a copy of any listed reference, if so requested by the Examiner.

Respectfully submitted,



Joseph Rossi, Reg. No. 47,038
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626
Aventis Docket No. USAV2001/0143 US CNT

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/787,367
				Filing Date	02/26/2004
				First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Coppins, Janet
				Attorney Docket Number	USA2001/0143 - US - CNT
Sheet	1	of	13		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		4,927,809		STUBER, et al.	05-22-1990
		5,424,325		ANDO, et al.	06-13-1995
		5,486,629		ZIMMERMAN, et al.	01-23-1996
		5,498,616		MALLANO, et al.	03-12-1996
		5,847,135		BEMIS, et al.	12-08-1998
		5,852,007		CHATTERJEE, et al.	12-22-1998
		5,874,424		BATCHELOR, et al.	02-23-1999
		5,998,390		RAMAMURTHY, et al.	12-07-1999
		6,004,833		SPRUCE, et al.	12-21-1999
		6,022,861		SCARBOROUGH, et al.	02-08-2000
		6,114,310		CHAMBERLAND, et al.	09-05-2000
		6,124,833		MILLER, et al.	12-26-2000
		6,255,453		GYORKOS	07-03-2001
		6,353,017		ALTMAN, et al.	03-05-2002
		6,455,502		BRYANT, et al.	09-24-2002
		6,476,026		BRYANT, et al.	11-05-2002
		6,492,382		GRAUPE, et al.	12-10-2002
		6,506,733		BUYSSE	01-14-2003
		6,576,630		LINK, et al.	06-10-2003

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴	Kind Code ² (if known)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		EP	EP 0272871		06-29-1988
		EP	EP 0291234		11-17-1998
		EP	EP 0355572		02-28-1990
		EP	EP 0378012		07-04-1990
		EP	EP 0419683		04-03-1991
		EP	EP 0536399		04-01-1993
		EP	EP 0652009		10-05-1995
		EP	EP 0754454		01-22-1997
		JP	JP 06192199		07-12-1994
		JP	JP 42009133		05-06-1967

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-98)

Approved for use through 10/31/99, OMB 0851-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				<p>Complete If Known</p>		
<p>Sheet</p>		<p>2</p>	<p>of</p>	<p>13</p>	<p>Application Number</p>	10/787,367
					<p>Filing Date</p>	02/26/2004
					<p>First Named Inventor</p>	GRAUPE
					<p>Group Art Unit</p>	1626
					<p>Examiner Name</p>	Coppins, Janet
					<p>Attorney Docket Number</p>	USA2001/0143 - US - CNT

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴			
		JP	JP 63303868	YOSHIDA, et al.	12-08-1988	
		WO	WO 00/48982	TUCKER, et al.	08-24-2000	
		WO	WO 00/49007	TUCKER, et al.	08-24-2000	
		WO	WO 00/49008	TUCKER, et al.	08-24-2000	
		WO	WO 00/51998	CYWIN, et al.	09-08-2000	
		WO	WO 00/59881	SINGH, et al.	10-12-2000	
		WO	WO 00/69855	QUIBELL, et al.	11-23-2000	
		WO	WO 01/09110	BEKKALI, et al.	02-08-2001	
		WO	WO 01/19796	GRAUPE, et al.	03-22-2001	
		WO	WO 01/19808	GRAUPE	03-22-2001	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/89. OMB 0651-0031
PATENT AND TRADEMARK OFFICE: U.S. DEPARTMENT OF COMMERCE
Collection of information is voluntary. OMB and GPO numbers

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/787,367
				Filing Date	02/26/2004
				First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Coppins, Janet
Sheet	3	of	13	Attorney Docket Number	USA2001/0143 - US - CNT

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
		WO	WO 01/19816	EMMANUEL, et al.	03-22-2001	
		WO	WO 01/30772	TUCKER, et al.	03-03-2001	
		WO	WO 01/55125	BOZSING, et al.	08-02-2001	
		WO	WO 01/58886	MISSBACH, M	08-16-2001	
		WO	WO 95/13069	MORRIELLO, et al.	05-18-1995	
		WO	WO 95/15309	JENKINS, et al.	06-08-1995	
		WO	WO 95/24982	HALLINAN, et al.	09-14-1995	
		WO	WO 96/21655	PEET, et al.	07-18-1996	
		WO	WO 96/30353	PALMER, et al	10-03-1996	
		WO	WO 96/40647	ZIMMERMAN, et al.	12-19-1996	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				<p>Complete if Known</p>	
Sheet	4	of	13	Application Number	10/787,367
				Filing Date	02/26/2004
				First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Coppins, Janet
				Attorney Docket Number	USA2001/0143 - US - CNT

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Paragraphs or Relevant Figures Appear
		Office ²	Number ³	Kind Code ⁴ (if known)		
		WO	WO 96/40744	MARLOWE, et al.	12-19-1996	
		WO	WO 96/41638	DOLLE, et al.	12-27-1996	
		WO	WO 97/03679	MALLANO, et al.	02-06-1997	
		WO	WO 98/01133	AIBE, et al.	01-15-1998	
		WO	WO 98/01428	DOMINGUEZ, et al.	01-15-1998	
		WO	WO 98/05336	MARQUIS, et al.	02-12-1998	
		WO	WO 98/08802	YAMASHITA, et al.	03-05-1998	
		WO	WO 98/08867	SHIONOGI, et al.	03-05-1998	
		WO	WO 98/21188	PRESTON, et al.	05-22-1998	
		WO	WO 98/23586	FLOYD, C.	06-04-1998	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached *Kinds of U.S. Patent Documents*. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				<p>Complete if Known</p>	
Sheet	5	of	13	Application Number	10/787,367
				Filing Date	02/26/2004
				First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Coppins, Janet
				Attorney Docket Number	USAV2001/0143 - US - CNT

Examiner Signature	Date Considered	
-----------------------	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/99. OMB 0651-0037
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(use as many sheets as necessary)			
Sheet	6	of	13
		Attorney Docket Number USAV2001/0143 - US - CNT	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		ADAMS, et al., Potent and Selective Inhibitors of the Proteasom: Dipeptidyl Boronic Acids, <i>Bioorganic & Medicinal Chemistry Letters</i> , 8: 333-338 (1998).
		ASHWORTH, et al., 4-Cyanothiazolidides as very potent, stable Inhibitors of dipeptidyl peptidase IV, <i>Bioorganic & Med. Chem. Letters</i> , B, Oxford, 6(22):2745-2748 (1996).
		BERGEMAN, et al., Studies on the reactivity of .alpha.-cyano.alpha.-isocyano alkanotes. Versatile synthons for the assembly of imidazoles, <i>Helv.Chim. ACTA</i> , 82(6):909-918 (1999).
		BILLSON, et al., The Design and Synthesis of Inhibitors of the Cysteinyl, <i>Bioorg. Med. Chem. Lett.</i> vol. 8, pp. 993-998, 1998
		BROMME, et al., Potent Inactivation of Cathepsins S and L, <i>Biol. Chem. Hoppe-Seyler.</i> vol. 376, No. 5, pp. 343-347, 1994.
		CHATTERJEE, et al., D-Amino Acid Containing, High-Affinity Inhibitors of Recombinant Human Calpain 1, <i>Journal of Medicinal Chemistry</i> , vol. 41, No. 15, p: 2663-2666 (1998).
		COHEN, et al., Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders, <i>Journal of Neuroimmunology</i> , 98: 29-36 (1999).
		DUFOUR, et al., Engineering nitrile hydratase activity into a cysteine protease by a single mutation, <i>Biochemistry</i> , US, Am. Chem. Soc., Easton, PA, 34(50):16382-16388 (1995).
		EDWARDS, et al., Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl α -Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole, <i>Journal of American Chemical Society</i> , vol. 114, No. 5, p 1854-1863 (1992).
		EVOLI, et al., abstract only, <i>Drugs</i> , 1996, 52(5), 682-70

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/787,367
(use as many sheets as necessary)				Filing Date	02/26/2004
Sheet	7	of	13	First Named Inventor	GRAUPE
				Group Art Unit	1628
				Examiner Name	Coppins, Janet
				Attorney Docket Number	USA2001/0143 - US - CNT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GOUR-SALIN, et al., Inhibition of papain by peptide nitriles: conversion of the nitrile group into other functionalities via the papain:nitrile thiomimidate ester adduct, Can. J. of Chem., CA, National Research Council, Ottawa, 69(8):1288-1297 (1991).	
		HALLEGUA, et al., Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, Lupus, 8: 241-251 (2000).	
		HANZLIK, et al., Reversible covalent binding of peptide nitriles to papain, Biochim. Biophys. Acta, vol. 1035, No. 1, 1990, pp. 62-70.	
		HARRIS, et al., Characteristics of a continuous fluorogenic assay for calpain I. Kinetic evaluation of peptide aldehydes, halomethyl ketones and jachalasina methyl ketones as inhibitors of the enzyme, Chemical Abstracts, 110:7, Bioorg. Med. Chem. Lett, 5(4) 393-398 (1995).	
		HEITMILLER, R.F., abstract only., Semin. Thorac. Cardiovasc. Surg., 1999, 11(1), 41-6	
		KATRITZKY, et al., Benzotriazole-assisted synthesis of alpha- (acylamino) nitriles and a conceptually novel method for peptide elongation, Chem. Soc., Perkin Trans. 1(7):1853-1857 (1990).	
		KHAMASHTA, et al., Expert. Opin. Investig. Drugs, 2000, 9(7), 1581-93.	
		KRANTZ, et al., Peptidyl (Acyloxy)methyl Ketones and the Quiescent, Biochemistry, vol. 30, pp. 4678-4687, 1991	
		LEVY, E.G., Baillieres Clin. Endocrinol. Metab., 1997, 11(3) 585-595	
		LI, et al., Aminoacylpiperidine-2-nitriles: Potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26), Archives of Biochem. and Biophys., 323(1)148-154 (1995).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/787,367
(use as many sheets as necessary)				Filing Date	02/26/2004
Sheet	8	of	13	First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Coppins, Janet
				Attorney Docket Number	USA2001/0143 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		LIPSHUTZ, et al., Chiral induction in originally racemic amino acids via 5-acyl and 5-acyloxyaminooxazoles, 1st, J. Chem. 27(1):49-55 (1986), abstract.		
		LIPSHUTZ, et al., Heterocycles as masked diamide/dipeptide equivalents. Formation and reactions of substituted 5-(acylamino)oxazoles as intermediates en route to the cyclopeptide alkaloids, J. Am. Chem. Soc., 105(26):7703-7713 (1983).		
		LIPSHUTZ, et al., Oxazolophanes as masked cyclopeptide alkaloid equivalents: cyclic peptide chemistry without peptide couplings, J. Am. Chem. Soc., 112(19):7032-7041 (1990).		
		MARQUIS, et al., Potent dipeptidylketone inhibitors of the cysteine protease cathepsin, Chemical Abstracts, 74: 581-588 (1999).		
		MCMATH, et al., Direct dialkylation of peptide nitriles. Application of the synthesis of 1-aminocyclopropane-1-carboxylic acid (Acc)-containing dipeptides, Bull. Soc. Chim. Fr. 134(1):105-110 (1997).		
		MORIYA, et al., Synthesis and Hypolipidemic Activities of 5-Thienyl-4-oxazoleacetic Acid Derivatives.sup.1, J. Med. Chem., 29: 333-341 (1986).		
		MOSER, et al., 130 Poly (dipeptamidinium)-Salze: definition und metoden zur präparativen herstellung, poly (dipeptamidinium) salts: definition and method of preparation, Helvetica Chimica ACTA, CH, Verlag, Basel 69:1224-1262 (1986).		
		NIPPON, K., Patent Abstracts of Japan, Publication No. 63301868, 013(197)(1988), abstract.		
		NORTH, et al., Synthetic studies towards cyclic peptides. Concise synthesis of thiazoline and thiazole containing amino acids, Tetrahedron, 46(24):8627-8290 (1990).		
		OGILVIE, et al., Peptidomimetic Inhibitors of the human cytomegalovirus protease, Journal of Medicinal Chemistry vol. 40 No. 25 (1997).		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/787,367
(use as many sheets as necessary)				Filing Date	02/26/2004
Sheet	9	of	13	First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Coppins, Janet
				Attorney Docket Number	USA2001/0143 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PICKEN, et al., Inhibition of bovine cathepsin B by amino acid-derived nitriles, Biochemical Society Transactions, vol. 18, No. 2, p:316 (1990).	
		PLIURA, et al., Comparative behavior of calpain and cathepsin B, Biochem. J. vol. 288, pp. 759-762, 1992	
		POLMAN, et al., Drug treatment of multiple sclerosis, BMJ, 321: 19-26 (2000).	
		RIESE, et al., Essential Role for Cathepsin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading, Immunity, 4: 357-366 (Apr. 1996).	
		SMITH, et al., New Inhibitors of Cysteine Proteinases, J. Am. Chem. Soc. vol. 110, No. 13, pp. 4429-4431, 1988	
		SUAVE, et al., Carboxylmodified amino acids and peptides, I An efficient method for the synthesis of monofunctionalized enamines and monofunctionalized methyl ketone derivatives from thioamides via episulfides and thioiminium salts, Tetrahedron Lett, 29:19 2295-2298 (1988).	
		SUZUE, S., Hepatic agents. I. Synthesis of aminocyl (and hydroxyacyl) aminoacetonitriles, Chem. and Pharm. Bull. (Tokyo) (1968), 16(8), 1417-32.	
		SUZUE, et al., Studies on Hepatic Agents, Chem. Pharm. Bull. vol. 16, No. 8, pp. 1417-1432, Aug. 1968.	
		SUZUKI, et al., Synthesis of 2-Aryl-4(3-thienyl)imidazole Derivatives with Antinflammatory Properties (sup.1), Chem. Pharm. Bull, 34(8): 3111-3120 (1996).	
		TAO, et al., Inhibition of Calpain By Peptidyl Heterocycles, Bioorganic & Medicinal Chemistry Letters, 6:24 3009-3112 (1996).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-98)

Approved for use through 10/31/99, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/787,367
(use as many sheets as necessary)		Filing Date	02/26/2004
Sheet	10	of	13
		First Named Inventor	GRAUPE
		Group Art Unit	1626
		Examiner Name	Coppins, Janet
		Attorney Docket Number	USA2001/0143 - US - CNT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		THOMPSON, et al., Carboxyl-modified amino acids and peptides as protease inhibitors, J. Med. Chem., 29(1):104-111 (1986).
		TSUTSUMI, et al., Synthesis and Structure-Activity Relationships of Peptidyl a-Keto Heterocycles as Novel Inhibitors of Prolyl Endopeptidase, Journal of Medicinal Chemistry, vol. 37, No. 21, p 3492-3502 (1994).
		VARGHA, E., Peptide derivatives. VI. N-protected di- and tripeptide nitriles, Stud. Univ. Babes-Bolyai, Ser. Chem., 13(2):31-5 (English abstract of article in Romanian) (1968).
		VARGHESE, The structure and resonance Raman spectra-structure correlations for methyloxycarbonyl-L-phenylalanyl-L-alanine ethyl dithioester, Can. J. Chem., 64(8):1668-1673 (1986).
		YAMADA, et al., Studies of unusual amino acids and their peptides. IX. The synthetic study of bottomycins B1 and B2, Bul. Chem. Soc., Jpn. 51(3):878-83 (1978), abstract.
		, Derwent Abstract of Japanese Patent Application 06-192199 , (Jul. 12, 1994).

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				<p>Complete if Known</p>	
Sheet	11	of	13	Application Number	10/787,367
				Filing Date	02/26/2004
				First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Coppins, Janet
				Attorney Docket Number	USAV2001/0143 - US - CNT

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Text
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
		JP	JP 2001-011037	SATO, et al.	01-16-2001		
		JP	JP 2001-055366	SATO, et al.	02-27-2001		
		WO	WO00/59881	SINGH, et al.	10-12-2000		
		WO	WO01/09169	SINGH, et al.	02-08-2001		
		WO	WO02/057248	QUIBELL, et al.	07-25-2002		
		WO	WO02/057249	QUIBELL, M	07-25-2002		
		WO	WO02/057270	QUIBELL, M	07-25-2002		
		WO	WO02/096892	OHMOTO, et al.	05-30-2002		
		WO	WO02/100849	HICKEY, et al.	12-19-2002		
		WO	WO02/20485	BEKKALI, et al.	03-14-2002		

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached *Kinds of U.S. Patent Documents*. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Application is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → PTO/SB/088 (10-98)
Approved for use through 10/31/99. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/787,367
Sheet	12	of	13	Filing Date	02/26/2004
				First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Coppins, Janet
				Attorney Docket Number	USA2001/0143 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CHAPMAN, et al., Emerging Roles for Cysteine Proteases in Human Biology, Ann. Rev. Physiol.; 1997; 59; pp.63-88.	
		DRANOFF, et al., Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development, Immunity; 1999; 10; pp.197-206.	
		FENWICK, et al., Diastereoselective Synthesis, Activity and Chiral Stability of Cyclic Alkoxyketone Inhibitors of Cathepsin K., Bioorg. Med. Chem. Lett.; 2001; 11(2); pp.199-202.	
		FENWICK, et al., Solid-phase Synthesis of Cyclic Alkoxyketones, Inhibitors of the Cysteine Protease Cathepsin K., Bioorg. Med. Chem. Lett.; 2001; 11(2); pp.195-198.	
		GREENSPAN, et al., Identification of Dipeptidyl Nitriles as Potent and Selective Inhibitors of cathepsin B Through Structure-based Drug Design, J. Med. Chem.; 2001; 44; pp.4524-4534.	
		LOWE, et al., Kinetic Specificity in Papain-catalyzed Hydrolyses, Biochem. J.; 1971; 124(1); pp.107-115.	
		MACIEWICZ, et al., A comparison of Four Cathepsins (B,L,N and S) with Collagenolytic Activity From Rabbit Spleen, Biochem J.; 1998; 256; pp.439-440.	
		MARQUIS, et al., Azeanone-based Inhibitors of Human and Rat Cathepsin K., J. Med. Chem.; 2000; 44(9); pp.1380-1395.	
		NAKAGAWA, et al., Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-induced Arthritis in Cathepsin S-null Mice, Immunity; 1999; 10; pp.207-217.	
		OTTO, et al., Cysteine Proteases and their Inhibitors, Chem. Rev.; 1997; 97; pp.133-171.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) Inside this box →

PTO/SB/088 (10-96)

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/787,387
				Filing Date	02/26/2004
				First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Coppins, Janet
Sheet	13	of	13	Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered
-----------------------	--	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**